Three years, a clin­i­cal hold and a death lat­er, Sarep­ta aban­dons part­nered piv­otal-stage gene ther­a­py

Sarep­ta is break­ing off a three-year li­cens­ing pact for a rare dis­ease gene ther­a­py can­di­date, leav­ing its for­mer part­ner on its own as it pre­pares for a piv­otal read­out in mid-year.

Ac­cord­ing to Lyso­gene, Sarep­ta re­turned the glob­al com­mer­cial rights for LYS-SAF302 af­ter “un­suc­cess­ful dis­cus­sions for trans­fer­ring back to Lyso­gene the re­spon­si­bil­i­ty for the glob­al com­mer­cial sup­ply of LYS-SAF302.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER